Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 47Terminated 4Withdrawn 3Recruiting 3Active not recruiting 2Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1

Conditions

Rhabdoid Tumor 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1

Interventions

pembrolizumab 438Carboplatin 321Nivolumab 293Cyclophosphamide 285Specimen Handling 257Paclitaxel 249Magnetic Resonance Spectroscopy 249Cisplatin 248Radiotherapy 218Dexamethasone 183Gemcitabine 177Biopsy 177durvalumab 169atezolizumab 149Doxorubicin 140Rituximab 138Lenalidomide 135Docetaxel 131Ipilimumab 130Bevacizumab 128Radiation 121Capecitabine 117Etoposide 116Oxaliplatin 114Fluorouracil 110Pemetrexed 109Radiosurgery 108fludarabine 106venetoclax 102Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × MLN 8237 × Clear all
NCT01695941 2026-04-13

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Lymphoid

Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT02114229 2026-03-17

SJATRT

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
125 enrolled

Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡